Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma

CNS Neurosci Ther. 2021 Aug;27(8):973-986. doi: 10.1111/cns.13654. Epub 2021 May 10.


Aims: Glioma is a highly invasive brain tumor, which makes prognosis challenging and renders patients resistant to various treatments. Induction of cell death is promising in cancer therapy. Ferroptosis, a recently discovered regulated cell death, can be induced for killing glioma cells. However, the prognostic prediction of ferroptosis-related genes (FRGs) in glioma remains elusive.

Methods: The mRNA expression profiles and gene variation and corresponding clinical data of glioma patients and NON-TUMOR control were downloaded from public databases. Risk score based on a FRGs signature was constructed in REMBRANDT cohort and validated in other datasets including CGGA-693, CGGA-325, and TCGA.

Results: Our results demonstrated that the majority of FRGs was differentially expressed among GBM, LGG, and NON-TUMOR groups (96.6%). Furthermore, the glioma patients with low-risk score exhibited a more satisfactory clinical outcome. The better prognosis was also validated in the glioma patients with low-risk score no matter to which grade they were affiliated. Functional analysis revealed that the high-risk score group was positively correlated with the enrichment scores for immune checkpoint blockade-related positive signatures, indicating the critical role of glioma immunotherapy via risk score.

Conclusion: A novel FRGs-related risk score can predict prognosis and immunotherapy in glioma patients.

Keywords: ferroptosis; gene signature; glioma; immunotherapy; prognosis; risk score.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / therapy
  • Cohort Studies
  • Databases, Genetic / trends
  • Ferroptosis / physiology*
  • Gene Expression Profiling / trends*
  • Gene Expression Regulation, Neoplastic / physiology
  • Glioma / diagnosis
  • Glioma / genetics*
  • Glioma / therapy
  • Humans
  • Immunotherapy / trends*
  • Predictive Value of Tests
  • Prognosis